<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ritsuro Suzuki, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Adult T cell leukemia-lymphoma (ATL) is a mature T cell malignancy that generally presents with widespread involvement of lymph nodes, peripheral blood, and/or skin [<a href="#rid1">1</a>]. Although ATL is often highly aggressive, the clinical presentation is variable and, in some cases, it is an indolent disorder. ATL is caused by chronic infection with the human T-lymphotropic virus, type I (HTLV-I).</p><p>This topic discusses the epidemiology, pathogenesis, clinical presentation, pathologic findings, and diagnosis of ATL.</p><p>Treatment of ATL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4736.html" rel="external">"Treatment and prognosis of adult T cell leukemia-lymphoma"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>ATL is an uncommon lymphoid neoplasm that occurs in patients with human T-lymphotropic virus, type I (HTLV-I) infection. Incidence varies by population according to the prevalence of HTLV-I infection [<a href="#rid2">2</a>]. Infection with HTLV-1 is endemic in several islands in southwestern Japan, the Caribbean basin (eg, Jamaica and Trinidad), western Africa, Peru, northeast Iran, and the southeastern portion of the United States; most affected patients live in or originate from these areas [<a href="#rid3">3-9</a>].</p><p>In the United States as a whole, the incidence of ATL is approximately 0.05 cases per 100,000 people [<a href="#rid10">10</a>]. ATL is more common in Black Americans and Asian/Pacific Islanders than White Americans and there is a slight male predominance overall [<a href="#rid11">11</a>]. The median age at diagnosis is in the sixth decade [<a href="#rid2">2,12</a>]. However, median age at diagnosis can vary with geographic location. As an example, a study of 126 patients with ATL from Jamaica reported a median age of 43 years [<a href="#rid13">13</a>].</p><p>Since ATL is associated with HTLV-I infection, patients with ATL are also at risk for HTLV-I-associated myelopathy, also known as tropical spastic paraparesis. HTLV-I-associated myelopathy is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/8317.html" rel="external">"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>ATL is uniformly associated with human T-lymphotropic virus type I (HTLV-I) infection of CD4-positive T cells, the cell of origin for the tumor [<a href="#rid14">14</a>]; this infection is thought to play a significant role in the pathogenesis of ATL. In xenograft models, the tumor-initiating cell appears to be an HTLV-I infected CD4-positive memory T cell with stem cell-like properties [<a href="#rid15">15</a>]. All of the malignant cells in a particular tumor share the same HTLV-I proviral genomic integration site. Since proviral integration is believed to occur in a more or less random fashion, the clonal nature of proviral integration sites in tumors indicates that viral infection and integration must occur prior to malignant transformation and clonal expansion. It is unclear whether the particular insertion location affects the phenotype of the cell (eg, by dysregulating nearby genes).</p><p>It is estimated that there are 5 to 10 million HTLV-1 carriers worldwide [<a href="#rid16">16</a>]. The long-term risk of developing ATL following infection with HTLV-I in endemic areas has been estimated to be 4 to 5 percent, usually after a latency period of several decades [<a href="#rid17">17,18</a>]. Exposure to the virus early in life increases the risk of eventual development of ATL. A shorter latency period has been noted in infected patients receiving treatment with immunosuppressive agents for other conditions [<a href="#rid19">19-21</a>]. The low incidence of ATL in HTLV-I infected individuals and the long latency period between HTLV-I infection and ATL development indicate that infection with HTLV-I alone is insufficient for malignant transformation [<a href="#rid14">14,22</a>]. It has been reported that clones of ATL cells with the same proviral integration site can have different T cell receptor rearrangements, raising the possibility that ATL may arise from immature HTLV-1 infected hematopoietic progenitors [<a href="#rid23">23</a>].</p><p>The exact mechanism by which HTLV-I contributes to tumor development is unknown. One suspect is the tax oncoprotein (the gene product of the viral gene <em>tax</em> [transactivating gene of the X region]) induces cellular proliferation, promotes cellular survival, and impairs DNA damage repair mechanisms [<a href="#rid24">24,25</a>]. Tax protein activates gene expression by acting on host transcription factors such as nuclear factor-kappa-B (NF-kB); tax protein results in migration of NF-kB from the cytoplasm to the nucleus where it activates genes responsible for cellular proliferation. In addition, tumor survival is promoted by the constitutive activation of the JAK-STAT pathway [<a href="#rid26">26,27</a>] and by the inactivation of the tumor suppressor TP53 [<a href="#rid28">28</a>].</p><p>Somatic mutations collaborate with HTLV-1 infection to cause lymphomagenesis. Mutations in <em>RHOA</em>, which encodes a GTP-binding protein, and <em>TET2</em>, an epigenetic regulator, are found in a subset of ATL cases [<a href="#rid29">29</a>]. <em>RHOA</em> and <em>TET2</em> mutations are also seen in other subtypes of peripheral T cell tumors (eg, angioimmunoblastic lymphoma). Although their functional contributions to ATL remain to be ascertained, work in other peripheral T cell lymphoma models has shown that mutated <em>RHOA</em> promotes lymphomagenesis, possibly by augmenting PI3K/AKT signaling downstream of ICOS, a T cell costimulatory protein [<a href="#rid30">30</a>]. Whole exome sequencing of 81 cases of ATL identified 50 genes that were recurrently mutated, including 13 genes that were mutated in more than 10 percent of the cases [<a href="#rid31">31</a>]. The most frequently mutated genes included <em>PLCG1 </em>(36 percent), <em>PRKCB </em>(33 percent), <em>CARD11 </em>(24 percent), <em>VAV1 </em>(18 percent), and <em>IRF4 </em>(14 percent), all of which are involved in signaling downstream of the T cell receptor and lead to activation of NF-kB. This same study noted that ATL cells often acquire copy number variants, some involving regions containing the genes cited above. Whole-genome sequencing of 150 cases uncovered additional acquired genetic events associated with ATL [<a href="#rid32">32</a>]. One-third of cases had loss-of-function mutations targeting the long isoform of CIC, a transcriptional repressor, while another 13 percent had gain-of-function mutations in <em>REL</em>, a gene encoding a member of the NF-kB transcription factor family. Other frequently affected genes include <em>TP53</em>, which is mutated in 10 to 50 percent of ATL [<a href="#rid33">33,34</a>]; and <em>RB1</em>, which is usually unmutated but may be suppressed through other mechanisms [<a href="#rid35">35,36</a>]. Finally, ATL is one of a number of cancers in which structural aberrations have been reported to lead to overexpression of the immune checkpoint protein PD-L1 [<a href="#rid37">37</a>], possibly pointing to an important role for immuno-evasion in its development and progression.</p><p>As described below, ATL is frequently associated with hypercalcemia, which can be severe. The hypercalcemia seen in ATL is paraneoplastic in origin and thought to arise from cytokines liberated from the malignant cells. (See  <a class="medical medical_review" href="/z/d/html/842.html" rel="external">"Hypercalcemia of malignancy: Mechanisms"</a>.)</p><p>The following mechanisms have been proposed as causes of hypercalcemia:</p><p class="bulletIndent1"><span class="glyph">●</span>Constitutive production of parathyroid hormone related protein (PTH-RP) [<a href="#rid38">38-40</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor necrosis factor-beta [<a href="#rid41">41</a>] or interleukin-1 [<a href="#rid42">42</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased expression of <em>RANKL </em>(receptor activator of nuclear factor kB ligand) [<a href="#rid43">43</a>]</p><p></p><p>These factors may also contribute to the genesis of the lytic bone lesions, increased bone turnover, increased serum alkaline phosphatase, and the "super scan" of the skeleton seen on radionuclide imaging [<a href="#rid44">44,45</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The clinical features of ATL include evidence of generalized lymphadenopathy, hepatosplenomegaly, immunosuppression, hypercalcemia, lytic bone lesions, and skin lesions. The frequency of these differs among patient groups and has been the basis on which clinical variants have been defined.</p><p class="headingAnchor" id="H5"><span class="h2">Clinical variants</span><span class="headingEndMark"> — </span>Several clinical variants of ATL have been described: acute, lymphomatous, chronic, and smoldering; these appear to have differing genomic alterations and different clinical courses [<a href="#rid46">46,47</a>]. Progression from chronic and smoldering disease to aggressive disease resembling the acute variant eventually occurs in up to 25 percent of cases, and may be associated with specific changes on gene expression profiling [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Acute</span><span class="headingEndMark"> — </span>The most common presentation of ATL, occurring in about 60 percent of cases, is the acute variant, which has a generally poor prognosis with survival measured in months to a year despite aggressive treatment [<a href="#rid47">47,49</a>]. (See  <a class="medical medical_review" href="/z/d/html/4736.html" rel="external">"Treatment and prognosis of adult T cell leukemia-lymphoma"</a>.)</p><p>Patients with the acute variant of ATL most frequently present with systemic symptoms, organomegaly, lymphadenopathy, an elevated lactate dehydrogenase (LDH) level, and circulating malignant cells. The white blood cell (WBC) count is usually elevated and may be higher than 100,000/microL. </p><p>Common presenting signs or symptoms include [<a href="#rid44">44,47,50-52</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A high peripheral blood white blood cell count is common due to the presence of circulating lymphocytes with highly abnormal convoluted nuclei  (<a class="graphic graphic_picture graphicRef82314" href="/z/d/graphic/82314.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow involvement is observed in 5 to 35 percent of cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphadenopathy is seen in almost all cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Involvement of the liver and spleen is present in approximately 16 and 22 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>40 to 50 percent will have hypercalcemia with or without lytic bone lesions at presentation and an additional third will develop hypercalcemia at some point during the course of their disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 25 percent will have skin lesions at diagnosis, often simulating those seen in mycosis fungoides. Skin lesions may be patches (7 percent), plaques (27 percent), papules (19 percent), tumors (39 percent), erythrodermic lesions (4 percent), and purpuric lesions (4 percent) [<a href="#rid53">53</a>]. The prognosis may vary with different types of skin lesions being better for those with patches or plaques and worst for patients with erythrodermic or purpuric lesions.</p><p></p><p>Less common clinical features may include [<a href="#rid54">54,55</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Interstitial pulmonary infiltrates, which may be due to pneumocystis jirovecii pneumonia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system involvement with mass lesions on imaging</p><p></p><p class="headingAnchor" id="H7"><span class="h3">Lymphomatous</span><span class="headingEndMark"> — </span>The lymphomatous variant accounts for approximately 20 percent of cases and is characterized by prominent lymphadenopathy without blood involvement. Patients frequently have an elevated LDH level and can have hypercalcemia. Prognosis is poor with a survival similar to that of patients with the acute variant.</p><p class="headingAnchor" id="H8"><span class="h3">Chronic</span><span class="headingEndMark"> — </span>Approximately 10 percent of cases are a chronic variant. These patients present with skin lesions, mild lymphadenopathy, leukocytosis, and an absolute lymphocytosis that may be stable for months to years [<a href="#rid56">56</a>]. Median survival is two to five years, however, there is a subgroup of patients with unfavorable chronic-type ATL, which is defined by a low serum albumin, high LDH, or high blood urea nitrogen concentration. These patients have a poor prognosis similar to that of the acute and lymphoma variants.</p><p class="headingAnchor" id="H9"><span class="h3">Smoldering</span><span class="headingEndMark"> — </span>The smoldering variant is least common, accounting for approximately 10 percent of cases. These patients are often asymptomatic except for skin and/or pulmonary lesions. They have normal blood lymphocyte counts with &lt;5 percent circulating neoplastic cells and normal calcium levels. Median survival without treatment is approximately three years [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H2931839225"><span class="h3">Primary cutaneous tumoral</span><span class="headingEndMark"> — </span>Primary cutaneous tumoral (PCT) ATL is a distinct subtype with cutaneous lesions that appear as rapidly growing tumors; it is a provisional subtype of ATL, according to a consensus meeting report [<a href="#rid57">57</a>]. The cutaneous manifestations are primarily nodulo-tumoral and pathologic findings reveal a pleomorphic high-grade T cell lymphoma with medium or large cells, prominent perivascular infiltration, and scant epidermotropism [<a href="#rid58">58</a>]. PCT-ATL is generally less aggressive than acute or lymphoma types, but it is more aggressive than chronic/smoldering type. It must be distinguished from other cutaneous T cell lymphomas, such as mycosis fungoides and peripheral T cell lymphoma. </p><p class="headingAnchor" id="H10"><span class="h2">Hypercalcemia and lytic bone lesions</span><span class="headingEndMark"> — </span>As mentioned above, the frequency of hypercalcemia and lytic bone lesions differs among the variants of ATL. In the acute variant, approximately 70 percent of patients with ATL will have hypercalcemia at some point in their disease course while 40 percent will have lytic bone lesions [<a href="#rid59">59</a>]. Hypercalcemia can be severe with calcium levels as high as 21 mg/dL (5.25 mmol/liter). Signs and symptoms related to hypercalcemia such as renal dysfunction or neuropsychiatric disturbances may be prominent among the presenting clinical features. The clinical manifestations of hypercalcemia are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/832.html" rel="external">"Clinical manifestations of hypercalcemia"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Immunosuppression</span><span class="headingEndMark"> — </span>Patients with ATL are immunosuppressed and at risk of developing opportunistic infections including pneumocystis jirovecii pneumonia, cryptococcus meningitis, and disseminated herpes zoster [<a href="#rid60">60</a>]. Severe, and often fatal, infestation by disseminated <em>Strongyloides stercoralis </em>is common as well. (See  <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">"Strongyloidiasis"</a>.)</p><p>A retrospective analysis of 818 patients with ATL found that 213 (26 percent) had infectious complications at the time of diagnosis [<a href="#rid61">61</a>]. Infectious complications were more common in patients with the acute, chronic, or smoldering variants than in patients with the lymphomatous variant. Of the 465 patients with acute variant ATL, the following infections were found at diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial (mostly pneumonia) in 55 patients (12 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Fungal (mostly cutaneous) in 38 patients (8 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Protozoal (mostly strongyloidiasis) in 22 patients (5 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Viral (mostly herpes zoster) in 13 patients (3 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>339 patients were without infection at diagnosis (73 percent)</p><p></p><p class="headingAnchor" id="H12"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H13"><span class="h2">Morphology</span><span class="headingEndMark"> — </span>The morphology of the tumor cells is quite variable from case to case, and a high index of suspicion on clinicopathologic grounds is helpful in arriving at an expeditious diagnosis. The organs involved vary, but can include the peripheral blood and bone marrow, lymph nodes, and skin.</p><p class="headingAnchor" id="H14"><span class="h3">Peripheral blood and bone marrow</span><span class="headingEndMark"> — </span>The most characteristic morphologic feature of ATL is seen in the peripheral blood of leukemic cases. In such cases, medium sized lymphocytes with condensed chromatin and bizarre hyperlobated nuclei ("clover leaf" or "flower cells") can be found, often resembling the Sézary cells of mycosis fungoides  (<a class="graphic graphic_picture graphicRef82314" href="/z/d/graphic/82314.html" rel="external">picture 1</a>) [<a href="#rid3">3</a>]. There is often a small proportion of blast-like cells with deeply basophilic cytoplasm, but not all ATL cells show morphologic atypia; many morphologically normal lymphocytes are leukemic cells. Bone marrow involvement is seen in approximately 35 percent of cases [<a href="#rid59">59</a>]. Bone marrow infiltrates are usually patchy, ranging from sparse to moderate.</p><p class="headingAnchor" id="H15"><span class="h3">Lymph nodes</span><span class="headingEndMark"> — </span>Involved lymph nodes typically display diffuse architectural effacement, although at early stages of involvement the cells may preferentially accumulate in the T cell areas or sinusoids of the node. A wide range of morphologies may be seen. Most commonly, the neoplastic cells are medium to large-sized with nuclear pleomorphism; the cytoplasm is amphophilic, basophilic, or pale. Reed-Sternberg–like cells and multinucleated giant cells with convoluted or cerebriform nuclei may be present, causing a resemblance to Hodgkin lymphoma [<a href="#rid62">62</a>]. Uncommonly, the tumor can be composed of small-sized lymphoid cells with nuclear pleomorphism, or may resemble anaplastic large cell lymphoma. Mitotic activity is variable. In the background, there is typically a mild to moderate proliferation of high endothelial venules.</p><p class="headingAnchor" id="H16"><span class="h3">Other tissues</span><span class="headingEndMark"> — </span>On occasion, ATL may present with skin infiltrates similar to those seen in cutaneous T cell lymphoma (mycosis fungoides), with epidermotropism and Pautrier's microabscesses; such cases are more likely to be associated with an indolent course. (See  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p>In a study of 71 patients with ATL from Japan, involvement of the stomach was documented by endoscopic biopsy in 21 (30 percent) [<a href="#rid63">63</a>]. The prevalence of infection with <em>Helicobacter pylori</em> was 86 versus 38 percent in those with or without gastric involvement, respectively.</p><p class="headingAnchor" id="H17"><span class="h2">Immunophenotype</span><span class="headingEndMark"> — </span>The origin of the malignant cell in ATL is a human T-lymphotropic virus, type I (HTLV-I) infected mature CD4+ T-lymphocyte. In a subset of cases, the tumor cells express the transcription factor FoxP3, a marker of immunosuppressive regulatory T cells (Tregs) [<a href="#rid64">64,65</a>]. For purposes of diagnosis, suspected cases should be stained for CD3, CD4, CD7, CD8, and CD25 at a minimum. Tumor cells express T cell associated antigens (CD2, CD4, and CD5), but usually lack CD7 and may exhibit dim CD3 expression. Most cases are CD4+ and CD8- [<a href="#rid59">59</a>]. Rare cases are CD4-/CD8+ or CD4+/CD8+. CD25 is expressed in a majority of the cases [<a href="#rid62">62,66</a>], as is CD52 [<a href="#rid49">49</a>]. Anaplastic large cell variants react with CD30, but are negative for ALK protein and lack rearrangements involving the ALK gene.</p><p class="headingAnchor" id="H18"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>There is no distinct molecular or karyotypic abnormality in ATL other than clonally integrated HTLV-1, which is observed in all malignant cells [<a href="#rid59">59</a>]. Karyotypic analysis is generally reserved for patients enrolled in clinical trials. The T cell receptor genes are clonally rearranged [<a href="#rid67">67</a>].</p><p>The most common karyotypic changes involve copy number alterations of 3q, 6q, and 14q, as well as inv(14) [<a href="#rid68">68</a>]. In three studies, the more clinically aggressive ATL variants had the most complex chromosomal abnormalities [<a href="#rid68">68-70</a>]. Mapping of chromosome 6q in 22 patients with ATL indicated deletions in nine tumors, eight of which shared the same deleted region (6q15-21), a possible site for a tumor-suppressor gene [<a href="#rid71">71</a>].</p><p>Deletion of the p16 gene, an important regulator of the cell cycle that is located on chromosome 9p, or reduced production of p16 protein may be associated with a more aggressive clinical course and reduced survival [<a href="#rid72">72,73</a>]. A further description of the p16 gene is presented separately. (See  <a class="medical medical_review" href="/z/d/html/7624.html" rel="external">"Inherited susceptibility to melanoma", section on 'CDKN2A gene'</a>.)</p><p>Somatic mutations in <em>RHOA</em>, which encodes a GTP-binding protein, and <em>TET2</em>, an epigenetic regulator, are seen in a subset of ATL cases [<a href="#rid29">29</a>], and in other peripheral T cell lymphomas, especially angioimmunoblastic lymphoma. As mentioned earlier, ATL commonly has mutations enhancing T cell receptor signaling that lead to NF-kB activation [<a href="#rid31">31</a>], loss-of-function mutations in <em>TP53</em> [<a href="#rid33">33,34</a>]; and structural aberrations leading to overexpression of PD-L1 [<a href="#rid37">37</a>] are also common in ATL. (See <a class="local">'Pathogenesis'</a> above.) </p><p class="headingAnchor" id="H19"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of ATL is based on a combination of characteristic clinical features, morphologic and immunophenotypic changes of the malignant cells, along with confirmation of human T-lymphotropic virus, type I (HTLV-I) infection [<a href="#rid74">74</a>]. Identification of at least 5 percent tumor cells by cytology and immunophenotype in the peripheral blood with confirmation of HTLV-1 infection is often sufficient to make the diagnosis in patients with acute, chronic, or smoldering type ATL [<a href="#rid61">61</a>]. Patients with lymphomatous lesions should undergo an excisional biopsy of an involved lymph node for histopathologic examination. Testing for clonal proviral integration is not routinely performed, and currently, the diagnosis is usually confirmed by tests for HTLV-1 specific antibodies and/or polymerase chain reaction (PCR)-based tests for the presence of provirus in peripheral blood cells.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – There are no pathognomonic clinical features that clearly distinguish ATL from other disorders. As previously described, a number of clinical variants have been defined. Common features include generalized lymphadenopathy, hepatosplenomegaly, immunosuppression, hypercalcemia, lytic bone lesions, and skin lesions. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HTLV-1 infection</strong> – Practically all patients with ATL have serologic antibodies to HTLV-I. An enzyme-linked immunosorbent assay (ELISA) is the most frequently used screening test, using antigens prepared from whole virus lysate or by recombinant technology. Western blotting (WB) is normally used for confirmatory testing. WB also distinguishes between infection with HTLV-I and the less pathogenic HTLV-II.</p><p></p><p class="bulletIndent1">PCR-based testing to detect proviral DNA in tumor cells should be performed in the rare instance where serology is negative but suspicion for ATL is high. This test will also differentiate HTLV-I from HTLV-II infection. Another diagnostic modality is RNA in situ hybridization for the HTLV-1 bZIP transcript (HBS), which appears to be highly sensitive and specific for diagnosing ATL when used on paraffin-embedded tumor samples that are less than two years old [<a href="#rid75">75</a>]. Details on the diagnosis of HTLV-I infection are presented separately. (See  <a class="medical medical_review" href="/z/d/html/8317.html" rel="external">"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histology</strong> – As described above, the tumor cell morphology is quite variable. The most characteristic morphologic changes seen in ATL is that of the circulating tumor cells, which are characterized by medium sized lymphocytes with condensed chromatin and bizarre hyperlobated nuclei ("clover leaf" or "flower cells")  (<a class="graphic graphic_picture graphicRef82314" href="/z/d/graphic/82314.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunophenotype</strong> – The immunophenotype is that of an activated mature T-lymphocyte. The most common immunophenotype is CD4+, CD25+, CD7-, and CD8-.</p><p></p><p class="headingAnchor" id="H20"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of ATL includes other T cell lymphoid malignancies such as cutaneous T cell lymphoma, T-prolymphocytic leukemia (T-PLL), anaplastic large cell lymphoma, and angioimmunoblastic T cell lymphoma. Some cases of ATL can resemble Hodgkin disease morphologically.</p><p class="headingAnchor" id="H182686910"><span class="h2">Asymptomatic healthy carriers of HTLV-1</span><span class="headingEndMark"> — </span>Flower cells similar to those seen in ATL can be seen in the peripheral blood of asymptomatic healthy carriers of human T-lymphotropic virus, type I (HTLV-1) [<a href="#rid76">76</a>]. Such cases may be difficult to distinguish from smoldering ATL. Southern blotting can be used to identify the clonal integration of HTLV-1 into the circulating cells of smoldering ATL [<a href="#rid77">77</a>], but is no longer available in most centers. An alternative is to use conventional polymerase chain reaction (PCR) testing for T cell receptor gene rearrangements, which can be used to determine if a clonal T cell population is emerging. (See  <a class="medical medical_review" href="/z/d/html/8316.html" rel="external">"Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Cutaneous T cell lymphoma</span><span class="headingEndMark"> — </span>ATL can be difficult to distinguish from forms of cutaneous T cell lymphoma (CTCL), such as mycosis fungoides and Sézary syndrome. Both of these disorders can have cutaneous manifestations with malignant T cells circulating in the peripheral blood and skin biopsy findings that are practically identical morphologically. They can also have a similar immunophenotype, as both may be CD4+, CD7-, and CD25+, though CD25 positivity usually is more variable in CTCL and confined to a minor subset of cells. The key distinguishing feature is the presence of HTLV-I in the malignant cells of ATL. (See  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">T-prolymphocytic leukemia</span><span class="headingEndMark"> — </span>Like ATL, T-prolymphocytic leukemia (T-PLL) is an aggressive malignancy. It is characterized by circulating malignant T lymphoid cells, marked lymphocytosis, cytopenias, and splenomegaly. Immunophenotype can help distinguish this disorder from ATL. As with ATL, T-PLL is CD4+. However, unlike ATL, T-PLL is CD7+ and CD25-. T-PLL is not associated with HTLV-I and &gt;80 percent of tumors have genetic abnormalities, usually an inversion of chromosome 14 that fuses the TCL1 gene to the T cell receptor alpha/delta locus and leads to the overexpression of TCL1 protein. (See  <a class="medical medical_review" href="/z/d/html/4745.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Anaplastic large cell lymphoma</span><span class="headingEndMark"> — </span>Anaplastic large cell lymphoma (ALCL) is another T cell lymphoid neoplasm that primarily involves the lymph nodes and skin but can demonstrate circulating malignant cells. Cell morphology is varied and the tumor cells may be CD4+ and CD7-, like ATL. Immunohistochemistry staining can be of help since ALCL has strong, uniform expression of CD30 with a membrane and Golgi distribution and is usually cytotoxic granule-associated protein positive.</p><p>The diagnosis of ALCL can be confirmed in many cases by demonstrating an <em>ALK1</em> gene rearrangement or expression of the ALK-1 protein, neither of which is found in ATL. The cutaneous variant of ALCL is much less likely than the systemic variant to demonstrate ALK-1 positivity and may be difficult to distinguish from ATL with cutaneous involvement; however, ALCL is not HTLV-1 associated, which is an important point of distinction. (See  <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)"</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Angioimmunoblastic T cell lymphoma</span><span class="headingEndMark"> — </span>Angioimmunoblastic T cell lymphoma (AITL) is one of the most common peripheral T cell lymphomas and usually presents with generalized systemic symptoms, lymphadenopathy, hepatomegaly, bone marrow involvement, and a pruritic skin rash. Most patients demonstrate a polyclonal hypergammaglobulinemia. The morphology of the malignant cells is varied but one common feature is the prominent arborizing high endothelial venules not typically found in ATL. Immunophenotyping typically demonstrates CD4 positivity and decreased intensity of CD7; however, the cell of origin of AITL is a follicular helper T cell, and the tumor cell of AITL bears certain immunophenotypic features of follicular helper T cells, such as expression of PD-1, CXCL13, CD10, and BCL6, that are absent for ATL. Finally, unlike ATL, AITL is not HTLV-I associated. (See  <a class="medical medical_review" href="/z/d/html/4727.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The treatment of ATL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4736.html" rel="external">"Treatment and prognosis of adult T cell leukemia-lymphoma"</a>.)</p><p class="headingAnchor" id="H1451354898"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117911.html" rel="external">"Society guideline links: Lymphoma diagnosis and staging"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Adult T cell leukemia-lymphoma (ATL) is an uncommon lymphoid neoplasm caused by human T-lymphotropic virus, type I (HTLV-I) infection. Incidence varies by population according to the prevalence of HTLV-I infection. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The long-term risk of developing ATL following infection with HTLV-I in endemic areas has been estimated to be 4 to 5 percent, usually after a latency period of several decades. The exact mechanism by which HTLV-I contributes to tumor development is unknown. However, the viral tax oncoprotein (encoded by the viral <em>tax</em> gene) is associated with increased cellular proliferation and survival, and impaired DNA damage repair mechanisms. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical features of ATL include evidence of generalized lymphadenopathy, hepatosplenomegaly, immunosuppression, hypercalcemia, lytic bone lesions, and skin lesions. The frequency of these differs among patient groups and has been the basis on which clinical variants have been defined. There are four basic clinical variants of ATL: acute (60 percent of cases), lymphomatous (20 percent of cases), chronic (10 percent of cases) and smoldering (10 percent of cases); in addition, primary cutaneous variant is a provisional subtype. ATL can progress from a chronic or smoldering variant to an aggressive disease resembling the acute variant. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most characteristic morphologic changes seen in the peripheral blood of ATL patients are cells with bizarre hyperlobulated nuclei ("clover leaf" or "flower cells")  (<a class="graphic graphic_picture graphicRef82314" href="/z/d/graphic/82314.html" rel="external">picture 1</a>). Bone marrow infiltrates are usually patchy. Involved lymph nodes typically display diffuse architectural effacement. Skin infiltrates can be similar to those seen in cutaneous T cell lymphoma (mycosis fungoides). (See <a class="local">'Morphology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cell of origin in ATL is an HTLV-I infected (CD4+) T cell that may reside in a long-lived pool of memory T cells with stem-like cells properties. In the majority of cases, the tumor cells also express other T cell associated antigens (CD2 and CD5), lack CD7, and express the IL-2 receptor, CD25. (See <a class="local">'Immunophenotype'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no distinct molecular or karyotypic abnormality in ATL. The T cell receptor genes are clonally rearranged, and all cases demonstrate clonally integrated HTLV-I. The more clinically aggressive ATL variants have the most complex chromosomal abnormalities. (See <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of ATL is based on a combination of specific clinical features, the morphology and immunophenotype of the malignant cells, and the presence of HTLV-I infection. The differential diagnosis of ATL includes other mature T cell lymphoid malignancies. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li><a class="nounderline abstract_t">Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26:4124.</a></li><li><a class="nounderline abstract_t">Jaffe ES, Blattner WA, Blayney DW, et al. The pathologic spectrum of adult T-cell leukemia/lymphoma in the United States. Human T-cell leukemia/lymphoma virus-associated lymphoid malignancies. Am J Surg Pathol 1984; 8:263.</a></li><li><a class="nounderline abstract_t">Picard FJ, Coulthart MB, Oger J, et al. Human T-lymphotropic virus type 1 in coastal natives of British Columbia: phylogenetic affinities and possible origins. J Virol 1995; 69:7248.</a></li><li><a class="nounderline abstract_t">Hjelle B, Khabbaz RF, Conway GA, et al. Prevalence of human T cell lymphotropic virus type II in American Indian populations of the southwestern United States. Am J Trop Med Hyg 1994; 51:11.</a></li><li><a class="nounderline abstract_t">Bitar N, Hajj HE, Houmani Z, et al. Adult T-cell leukemia/lymphoma in the Middle East: first report of two cases from Lebanon. Transfusion 2009; 49:1859.</a></li><li><a class="nounderline abstract_t">Phillips AA, Shapira I, Willim RD, et al. A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer 2010; 116:3438.</a></li><li><a class="nounderline abstract_t">Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012; 120:4795.</a></li><li><a class="nounderline abstract_t">Chihara D, Ito H, Matsuda T, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 2014; 164:536.</a></li><li><a class="nounderline abstract_t">Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008; 19:379.</a></li><li><a class="nounderline abstract_t">Adams SV, Newcomb PA, Shustov AR. Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States. J Clin Oncol 2016; 34:963.</a></li><li><a class="nounderline abstract_t">Matutes E. Adult T-cell leukaemia/lymphoma. J Clin Pathol 2007; 60:1373.</a></li><li><a class="nounderline abstract_t">Hanchard B. Adult T-cell leukemia/lymphoma in Jamaica: 1986-1995. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13 Suppl 1:S20.</a></li><li><a class="nounderline abstract_t">Smith MR, Greene WC. Molecular biology of the type I human T-cell leukemia virus (HTLV-I) and adult T-cell leukemia. J Clin Invest 1991; 87:761.</a></li><li><a class="nounderline abstract_t">Nagai Y, Kawahara M, Hishizawa M, et al. T memory stem cells are the hierarchical apex of adult T-cell leukemia. Blood 2015; 125:3527.</a></li><li><a class="nounderline abstract_t">Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol 2012; 3:388.</a></li><li><a class="nounderline abstract_t">Murphy EL, Hanchard B, Figueroa JP, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989; 43:250.</a></li><li><a class="nounderline abstract_t">Matsuoka M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 2003; 22:5131.</a></li><li><a class="nounderline abstract_t">Chen YC, Wang CH, Su IJ, et al. Infection of human T-cell leukemia virus type I and development of human T-cell leukemia lymphoma in patients with hematologic neoplasms: a possible linkage to blood transfusion. Blood 1989; 74:388.</a></li><li><a class="nounderline abstract_t">Hoshida Y, Li T, Dong Z, et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer 2001; 91:869.</a></li><li><a class="nounderline abstract_t">Tamaki H, Matsuoka M. Donor-derived T-cell leukemia after bone marrow transplantation. N Engl J Med 2006; 354:1758.</a></li><li><a class="nounderline abstract_t">Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007; 7:270.</a></li><li><a class="nounderline abstract_t">Rauch DA, Conlon KC, Janakiram M, et al. Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. Blood 2019; 134:1406.</a></li><li><a class="nounderline abstract_t">Taylor G. Molecular aspects of HTLV-I infection and adult T-cell leukaemia/lymphoma. J Clin Pathol 2007; 60:1392.</a></li><li><a class="nounderline abstract_t">Matsuoka M, Watanabe T, Kannagi M, et al. Meeting report on the 13th International Conference on Human Retrovirology: human T-cell leukemia virus research 30 years after adult T-cell leukemia. Cancer Res 2007; 67:10638.</a></li><li><a class="nounderline abstract_t">Migone TS, Lin JX, Cereseto A, et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 1995; 269:79.</a></li><li><a class="nounderline abstract_t">Ju W, Zhang M, Jiang JK, et al. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood 2011; 117:1938.</a></li><li><a class="nounderline abstract_t">Jeong SJ, Radonovich M, Brady JN, Pise-Masison CA. HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity. Blood 2004; 104:1490.</a></li><li><a class="nounderline abstract_t">Nagata Y, Kontani K, Enami T, et al. Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood 2016; 127:596.</a></li><li><a class="nounderline abstract_t">Cortes JR, Ambesi-Impiombato A, Couronné L, et al. RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis. Cancer Cell 2018; 33:259.</a></li><li><a class="nounderline abstract_t">Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet 2015; 47:1304.</a></li><li><a class="nounderline abstract_t">Kogure Y, Kameda T, Koya J, et al. Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood 2022; 139:967.</a></li><li><a class="nounderline abstract_t">Sakashita A, Hattori T, Miller CW, et al. Mutations of the p53 gene in adult T-cell leukemia. Blood 1992; 79:477.</a></li><li><a class="nounderline abstract_t">Cesarman E, Chadburn A, Inghirami G, et al. Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. Blood 1992; 80:3205.</a></li><li><a class="nounderline abstract_t">Hangaishi A, Ogawa S, Imamura N, et al. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood 1996; 87:4949.</a></li><li><a class="nounderline abstract_t">Nakayama K, Yamada Y, Koji T, et al. Expression and phosphorylation status of retinoblastoma protein in adult T-cell leukemia/lymphoma. Leuk Res 2000; 24:299.</a></li><li><a class="nounderline abstract_t">Kataoka K, Shiraishi Y, Takeda Y, et al. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 2016; 534:402.</a></li><li><a class="nounderline abstract_t">Motokura T, Fukumoto S, Matsumoto T, et al. Parathyroid hormone-related protein in adult T-cell leukemia-lymphoma. Ann Intern Med 1989; 111:484.</a></li><li><a class="nounderline abstract_t">Ikeda K, Ohno H, Hane M, et al. Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. J Clin Endocrinol Metab 1994; 79:1322.</a></li><li><a class="nounderline abstract_t">Nakamura Y, Bando H, Shintani Y, et al. Serum parathyroid hormone-related protein concentrations in patients with hematologic malignancies or solid tumors. Acta Endocrinol (Copenh) 1992; 127:324.</a></li><li><a class="nounderline abstract_t">Ishibashi K, Ishitsuka K, Chuman Y, et al. Tumor necrosis factor-beta in the serum of adult T-cell leukemia with hypercalcemia. Blood 1991; 77:2451.</a></li><li><a class="nounderline abstract_t">Wano Y, Hattori T, Matsuoka M, et al. Interleukin 1 gene expression in adult T cell leukemia. J Clin Invest 1987; 80:911.</a></li><li><a class="nounderline abstract_t">Nosaka K, Miyamoto T, Sakai T, et al. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 2002; 99:634.</a></li><li><a class="nounderline abstract_t">Bunn PA Jr, Schechter GP, Jaffe E, et al. Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med 1983; 309:257.</a></li><li><a class="nounderline abstract_t">Yamaguchi T, Hirano T, Kumagai K, et al. Osteitis fibrosa cystica generalizata with adult T-cell leukaemia: a case report. Br J Haematol 1999; 107:892.</a></li><li><a class="nounderline abstract_t">Oshiro A, Tagawa H, Ohshima K, et al. Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 2006; 107:4500.</a></li><li><a class="nounderline abstract_t">Katsuya H, Ishitsuka K, Utsunomiya A, et al. Treatment and survival among 1594 patients with ATL. Blood 2015; 126:2570.</a></li><li><a class="nounderline abstract_t">Tsukasaki K, Tanosaki S, DeVos S, et al. Identifying progression-associated genes in adult T-cell leukemia/lymphoma by using oligonucleotide microarrays. Int J Cancer 2004; 109:875.</a></li><li><a class="nounderline abstract_t">Ravandi F, O'Brien S. Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 2005; 80:1660.</a></li><li><a class="nounderline abstract_t">Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50:481.</a></li><li><a class="nounderline abstract_t">Foss FM, Aquino SL, Ferry JA. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-2003. A 72-year-old man with rapidly progressive leukemia, rash, and multiorgan failure. N Engl J Med 2003; 348:1267.</a></li><li><a class="nounderline abstract_t">Yamada Y, Kamihira S, Murata K, et al. Frequent hepatic involvement in adult T cell leukemia: comparison with non-Hodgkin's lymphoma. Leuk Lymphoma 1997; 26:327.</a></li><li><a class="nounderline abstract_t">Sawada Y, Hino R, Hama K, et al. Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood 2011; 117:3961.</a></li><li><a class="nounderline abstract_t">Okada F, Ando Y, Kondo Y, et al. Thoracic CT findings of adult T-cell leukemia or lymphoma. AJR Am J Roentgenol 2004; 182:761.</a></li><li><a class="nounderline abstract_t">Kawasaki C, Ikeda H, Fukumoto T. Cerebral mass lesions associated with adult T-cell leukemia/lymphoma. Int J Hematol 1995; 61:97.</a></li><li><a class="nounderline abstract_t">Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 2010; 115:4337.</a></li><li><a class="nounderline abstract_t">Cook LB, Fuji S, Hermine O, et al. Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol 2019; 37:677.</a></li><li><a class="nounderline abstract_t">Tsukasaki K, Imaizumi Y, Tokura Y, et al. Meeting report on the possible proposal of an extranodal primary cutaneous variant in the lymphoma type of adult T-cell leukemia-lymphoma. J Dermatol 2014; 41:26.</a></li><li><a class="nounderline abstract_t">Chadburn A, Athan E, Wieczorek R, Knowles DM. Detection and characterization of human T-cell lymphotropic virus type I (HTLV-I) associated T-cell neoplasms in an HTLV-I nonendemic region by polymerase chain reaction. Blood 1991; 77:2419.</a></li><li><a class="nounderline abstract_t">Verdonck K, González E, Van Dooren S, et al. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007; 7:266.</a></li><li><a class="nounderline abstract_t">Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991; 79:428.</a></li><li><a class="nounderline abstract_t">Kikuchi M, Mitsui T, Takeshita M, et al. Virus associated adult T-cell leukemia (ATL) in Japan: clinical, histological and immunological studies. Hematol Oncol 1986; 4:67.</a></li><li><a class="nounderline abstract_t">Ohnita K, Isomoto H, Mizuta Y, et al. Helicobacter pylori infection in patients with gastric involvement by adult T-cell leukemia/lymphoma. Cancer 2002; 94:1507.</a></li><li><a class="nounderline abstract_t">Roncador G, Garcia JF, Garcia JF, et al. FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia 2005; 19:2247.</a></li><li><a class="nounderline abstract_t">Karube K, Ohshima K, Tsuchiya T, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 2004; 126:81.</a></li><li><a class="nounderline abstract_t">Waldmann TA, Greene WC, Sarin PS, et al. Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor. J Clin Invest 1984; 73:1711.</a></li><li><a class="nounderline abstract_t">Aisenberg AC, Krontiris TG, Mak TW, Wilkes BM. Rearrangement of the gene for the beta chain of the T-cell receptor in T-cell chronic lymphocytic leukemia and related disorders. N Engl J Med 1985; 313:529.</a></li><li><a class="nounderline abstract_t">Sanada I, Tanaka R, Kumagai E, et al. Chromosomal aberrations in adult T cell leukemia: relationship to the clinical severity. Blood 1985; 65:649.</a></li><li><a class="nounderline abstract_t">Itoyama T, Chaganti RS, Yamada Y, et al. Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. Blood 2001; 97:3612.</a></li><li><a class="nounderline abstract_t">Tsukasaki K, Krebs J, Nagai K, et al. Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: correlation with clinical course. Blood 2001; 97:3875.</a></li><li><a class="nounderline abstract_t">Hatta Y, Yamada Y, Tomonaga M, et al. Detailed deletion mapping of the long arm of chromosome 6 in adult T-cell leukemia. Blood 1999; 93:613.</a></li><li><a class="nounderline abstract_t">Pombo-de-Oliveira MS, Dobbin JA, Loureiro P, et al. Genetic mutation and early onset of T-cell leukemia in pediatric patients infected at birth with HTLV-I. Leuk Res 2002; 26:155.</a></li><li><a class="nounderline abstract_t">Takasaki Y, Yamada Y, Sugahara K, et al. Interruption of p16 gene expression in adult T-cell leukaemia/lymphoma: clinical correlation. Br J Haematol 2003; 122:253.</a></li><li><a class="nounderline abstract_t">Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 2009; 27:453.</a></li><li><a class="nounderline abstract_t">Takatori M, Sakihama S, Miyara M, et al. A new diagnostic algorithm using biopsy specimens in adult T-cell leukemia/lymphoma: combination of RNA in situ hybridization and quantitative PCR for HTLV-1. Mod Pathol 2021; 34:51.</a></li><li><a class="nounderline abstract_t">Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol 1995; 69:2863.</a></li><li><a class="nounderline abstract_t">Tsukasaki K, Tsushima H, Yamamura M, et al. Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood 1997; 89:948.</a></li></ol></div><div id="topicVersionRevision">Topic 4697 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626005" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6324600" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The pathologic spectrum of adult T-cell leukemia/lymphoma in the United States. Human T-cell leukemia/lymphoma virus-associated lymphoid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7474147" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Human T-lymphotropic virus type 1 in coastal natives of British Columbia: phylogenetic affinities and possible origins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8059909" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence of human T cell lymphotropic virus type II in American Indian populations of the southwestern United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19453978" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adult T-cell leukemia/lymphoma in the Middle East: first report of two cases from Lebanon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20564100" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23086753" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24245986" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Differences in incidence and trends of haematological malignancies in Japan and the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18064533" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26962200" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18042693" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adult T-cell leukaemia/lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8797699" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Adult T-cell leukemia/lymphoma in Jamaica: 1986-1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1999493" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Molecular biology of the type I human T-cell leukemia virus (HTLV-I) and adult T-cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25847015" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : T memory stem cells are the hierarchical apex of adult T-cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23162541" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Epidemiological Aspects and World Distribution of HTLV-1 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2917802" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12910250" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Human T-cell leukemia virus type I and adult T-cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2752118" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Infection of human T-cell leukemia virus type I and development of human T-cell leukemia lymphoma in patients with hematologic neoplasms: a possible linkage to blood transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11275994" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Lymphoproliferative disorders in renal transplant patients in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625020" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Donor-derived T-cell leukemia after bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17384582" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31467059" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18042695" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Molecular aspects of HTLV-I infection and adult T-cell leukaemia/lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17993628" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Meeting report on the 13th International Conference on Human Retrovirology: human T-cell leukemia virus research 30 years after adult T-cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7604283" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21106989" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15155458" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26574607" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Variegated RHOA mutations in adult T-cell leukemia/lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29398449" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26437031" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Integrated molecular analysis of adult T cell leukemia/lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34695199" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Whole-genome landscape of adult T-cell leukemia/lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1730092" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mutations of the p53 gene in adult T-cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1361372" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8652807" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10713327" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Expression and phosphorylation status of retinoblastoma protein in adult T-cell leukemia/lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27281199" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2549824" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Parathyroid hormone-related protein in adult T-cell leukemia-lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7962324" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1280391" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Serum parathyroid hormone-related protein concentrations in patients with hematologic malignancies or solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2039827" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Tumor necrosis factor-beta in the serum of adult T-cell leukemia with hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2887587" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Interleukin 1 gene expression in adult T cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781248" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6602943" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical course of retrovirus-associated adult T-cell lymphoma in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10606900" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Osteitis fibrosa cystica generalizata with adult T-cell leukaemia: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16484591" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26361794" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Treatment and survival among 1594 patients with ATL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15027121" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Identifying progression-associated genes in adult T-cell leukemia/lymphoma by using oligonucleotide microarrays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16342661" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/301762" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Adult T-cell leukemia: clinical and hematologic features of 16 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12660391" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-2003. A 72-year-old man with rapidly progressive leukemia, rash, and multiorgan failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9322895" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Frequent hepatic involvement in adult T cell leukemia: comparison with non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21325600" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14975983" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Thoracic CT findings of adult T-cell leukemia or lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7734717" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cerebral mass lesions associated with adult T-cell leukemia/lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20348391" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Long-term study of indolent adult T-cell leukemia-lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30657736" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24438141" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Meeting report on the possible proposal of an extranodal primary cutaneous variant in the lymphoma type of adult T-cell leukemia-lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2039822" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Detection and characterization of human T-cell lymphotropic virus type I (HTLV-I) associated T-cell neoplasms in an HTLV-I nonendemic region by polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17376384" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Human T-lymphotropic virus 1: recent knowledge about an ancient infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1751370" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3009299" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Virus associated adult T-cell leukemia (ATL) in Japan: clinical, histological and immunological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920508" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Helicobacter pylori infection in patients with gastric involvement by adult T-cell leukemia/lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16193085" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15198736" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6327770" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2862584" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Rearrangement of the gene for the beta chain of the T-cell receptor in T-cell chronic lymphocytic leukemia and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3871643" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Chromosomal aberrations in adult T cell leukemia: relationship to the clinical severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11369658" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11389029" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: correlation with clinical course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9885223" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Detailed deletion mapping of the long arm of chromosome 6 in adult T-cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11755465" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Genetic mutation and early onset of T-cell leukemia in pediatric patients infected at birth with HTLV-I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12846894" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Interruption of p16 gene expression in adult T-cell leukaemia/lymphoma: clinical correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064971" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32801340" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A new diagnostic algorithm using biopsy specimens in adult T-cell leukemia/lymphoma: combination of RNA in situ hybridization and quantitative PCR for HTLV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7707509" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9028326" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
